Home › Opioid Overdose › NCT07129902
Contingency Management to Improve Medication for Opioid Use Disorder Continuation After the Emergency Department
Contingency Management to Improve Medication for Opioid Use Disorder Continuation After Discharge From the Emergency Department
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Major inclusion criteria include * STAR referral to outpatient clinic (Addiction Treatment Center and Chittenden Clinic) with prescription for buprenorphine or methadone. * Age ≥18 years. * Provide informed consent. Exclusion Criteria * Pending incarceration in the next 30 days. * Plan to leave the area (Burlington/Chittenden County) in the next 30 days. * Physical, health, or structural challenge that prevents attendance at outpatient clinic.
About the study
Project Summary The goal of this pilot clinical trial is to assess contingency management (CM) for increasing attendance at outpatient clinics after Medication for Opioid Use Disorder (MOUD) prescription and clinic referral occurred in the hospital Emergency Department (ED).
* The researchers will compare usual care (UC)+CM to UC alone to see if 1) CM works to promote MOUD clinic attendance after discharge from the ED and 2) demonstrate feasibility of providing CM in the ED and outpatient MOUD clinic settings. * Researchers will randomize 30 adults who started MOUD in the ED into two conditions. These conditions consist of (A) UC alone: A referral to an outpatient buprenorphine or methadone provider with reminders from STAR program staff or (B) UC+CM: UC plus financial incentives dependent on MOUD clinic attendance to receive an MOUD prescription.
The primary outcome of interest is the number of participants who receive their first MOUD prescription from the outpatient clinic after discharge from the ED in UC+CM compared to the UC-only condition. A secondary outcome will be the proportion of participants who kept attending outpatient MOUD treatment by the end of the 30-day study period between UC+CM and UC conditions. An exploratory outcome will be biochemically-verified illicit opioid abstinence measured at day 30.
What is being tested
- Contingency Management (behavioral)
- Usual care as prescribed by the ED physicians (behavioral)
Sponsor: University of Vermont · Participants: 30 · Started: Sep 2, 2025
Contact the study team
- Eric A Thrailkill, Ph.D. · Phone: 602-291-7311
Official record on ClinicalTrials.gov — NCT07129902
Locations in the U.S.
| Vermont | University of Vermont Medical Center, Burlington |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.